Publicaciones (211) Publicaciones en las que ha participado algún/a investigador/a

2023

  1. Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19

    Infectious Diseases Now, Vol. 53, Núm. 7

  2. Differences in the inflammatory response among hospitalized patients with distinct variants of SARS-CoV-2

    Frontiers in Immunology, Vol. 14

  3. Faster lung function decline in people living with HIV despite adequate treatment: A longitudinal matched cohort study

    Thorax, Vol. 78, Núm. 6, pp. 535-542

  4. Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; the HOPE-Covid-19 Registry

    Anti-Infective Agents, Vol. 21, Núm. 2, pp. 66-78

  5. Impact of the COVID-19 pandemic on the mental health of the general population and health care workers

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 2, pp. 125-143

  6. Monitoring monkeypox virus in saliva and air samples in Spain: a cross-sectional study

    The Lancet Microbe, Vol. 4, Núm. 1, pp. e21-e28

  7. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

  8. Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  9. Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

    Scientific Reports, Vol. 13, Núm. 1

  10. Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors

    Biomedicines, Vol. 11, Núm. 4

  11. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701

  12. TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

    Thorax, Vol. 78, Núm. 8, pp. 816-824

  13. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125

  14. Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort

    Journal of Clinical Medicine, Vol. 12, Núm. 3